Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders

Sudhir M Baswan, Allison E Klosner, Kelly Glynn, Arun Rajgopal, Kausar Malik, Sunghan Yim, Nathan Stern, Sudhir M Baswan, Allison E Klosner, Kelly Glynn, Arun Rajgopal, Kausar Malik, Sunghan Yim, Nathan Stern

Abstract

Though there is limited research confirming the purported topical benefits of cannabinoids, it is certain that cutaneous biology is modulated by the human endocannabinoid system (ECS). Receptors from the ECS have been identified in the skin and systemic abuse of synthetic cannabinoids, and their analogs, have also been associated with the manifestation of dermatological disorders, indicating the effects of the ECS on cutaneous biology. In particular, cannabidiol (CBD), a non-psychoactive compound from the cannabis plant, has garnered significant attention in recent years for its anecdotal therapeutic potential for various pathologies, including skin and cosmetic disorders. Though a body of preclinical evidence suggests topical application of CBD may be efficacious for some skin disorders, such as eczema, psoriasis, pruritis, and inflammatory conditions, confirmed clinical efficacy and elucidation of underlying molecular mechanisms have yet to be fully identified. This article provides an update on the advances in CBD research to date and the potential areas of future exploration.

Keywords: AEA; CB1; CB2; CBD; FAAH; cannabidiol; cannabinoids; endocannabinoid system; endocannabinoids; skin.

Conflict of interest statement

All the authors are employees of Amway Corporation which has commercial offerings in the wellness space. The authors report no other potential conflicts of interest for this work.

© 2020 Baswan et al.

Figures

Figure 1
Figure 1
Schematic representation of the key components of the ECS in different cellular compartments of the skin.
Figure 2
Figure 2
Modulation of the ECS by endocannabinoids and phytocannabinoids in presynaptic neurons in the central and peripheral nervous systems.
Figure 3
Figure 3
Chemical Structures of 9 endocannabinoids found in human skin.
Figure 4
Figure 4
Chemical structures of the most common phytocannabinoids found in the hemp plant.

References

    1. Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol. 1998;359(1):1–18. doi:10.1016/S0014-2999(98)00649-9
    1. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol. 2008;160:1–24. doi:10.1007/112_0505
    1. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(S1):S163–S171.
    1. Tóth KF, Ádám D, Bíró T, Oláh A. Cannabinoid signaling in the skin: therapeutic potential of the “C (ut) annabinoid” system. Molecules. 2019;24(5):918.
    1. Tüting T, Gaffal E. Chapter 57 - regulatory role of cannabinoids for skin barrier functions and cutaneous inflammation In: Preedy VR, editor. Handbook of Cannabis and Related Pathologies. San Diego: Academic Press; 2017:543–549.
    1. Mounessa JS, Siegel JA, Dunnick CA, Dellavalle RP. The role of cannabinoids in dermatology. J Am Acad Dermatol. 2017;77(1):188–190.
    1. Sugawara K, Biro T, Tsuruta D, et al. Endocannabinoids limit excessive mast cell maturation and activation in human skin. J Allergy Clin Immunol. 2012;129(3):726–738.e728.
    1. Devane WA, Dysarz F, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605–613.
    1. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–1949.
    1. Kendall AC, Pilkington SM, Massey KA, Sassano G, Rhodes LE, Nicolaou A. Distribution of bioactive lipid mediators in human skin. J Invest Dermatol. 2015;135(6):1510–1520. doi:10.1038/jid.2015.41
    1. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215(1):89–97. doi:10.1006/bbrc.1995.2437
    1. Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50(1):83–90. doi:10.1016/0006-2952(95)00109-D
    1. Gegotek A, Biernacki M, Ambrozewicz E, Surazynski A, Wronski A, Skrzydlewska E. The cross-talk between electrophiles, antioxidant defence and the endocannabinoid system in fibroblasts and keratinocytes after UVA and UVB irradiation. J Dermatol Sci. 2016;81(2):107–117. doi:10.1016/j.jdermsci.2015.11.005
    1. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev. 2008;108(5):1687–1707. doi:10.1021/cr0782067
    1. Liu J, Wang L, Harvey-White J, et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology. 2008;54(1):1–7. doi:10.1016/j.neuropharm.2007.05.020
    1. Maccarrone M, Di Rienzo M, Battista N, et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem. 2003;278(36):33896–33903. doi:10.1074/jbc.M303994200
    1. Paradisi A, Pasquariello N, Barcaroli D, Maccarrone M. Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. J Biological Chemistry. 2008;283(10):6005–6012. doi:10.1074/jbc.M707964200
    1. Lynch ME, Ware MA. Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol. 2015;10(2):293–301.
    1. Sonja Ständer S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. 2005;38(3):177–188. doi:10.1016/j.jdermsci.2005.01.007
    1. Tóth BI, Dobrosi N, Dajnoki A, et al. Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. J Investigative Dermatol. 2011;131(5):1095–1104.
    1. Pucci M, Pasquariello N, Battista N, et al. Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor. J Biol Chem. 2012;287(19):15466–15478.
    1. Czifra G, Szollosi AG, Toth BI, et al. Endocannabinoids regulate growth and survival of human eccrine sweat gland-derived epithelial cells. J Invest Dermatol. 2012;132(8):1967–1976.
    1. Rio CD, Millan E, Garcia V, Appendino G, DeMesa J, Munoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem Pharmacol. 2018;157:122–133.
    1. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biological Chemistry. 2004;279(7):5298–5305.
    1. Bisogno T, Melck D, Bobrov MY, et al. N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical J. 2000;351(3):817–824.
    1. Petrocellis LD, Cascio MG, Marzo VD. The endocannabinoid system: a general view and latest additions. Br J Pharmacol. 2004;141(5):765–774.
    1. Callaway J. Hempseed as a nutritional resource: an overview. Euphytica. 2004;140(1–2):65–72.
    1. Brighenti V, Pellati F, Steinbach M, Maran D, Benvenuti S. Development of a new extraction technique and HPLC method for the analysis of non-psychoactive cannabinoids in fibre-type Cannabis sativa L. (hemp). J Pharm Biomed Anal. 2017;143:228–236.
    1. Vuerich M, Ferfuia C, Zuliani F, Piani B, Sepulcri A. Yield and quality of essential oils in hemp varieties in different environments. Agronomy. 2019;9(7):356.
    1. Grijó DR, Osorio IAV, Cardozo-Filho L. Supercritical extraction strategies using CO2 and ethanol to obtain cannabinoid compounds from Cannabis hybrid flowers. J CO2 Utilization. 2019;30:241–248.
    1. Chemspider. Available from: . Accessed May3, 2020.
    1. Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E. Cannabidiol—transdermal delivery and anti-inflammatory effect in a murine model. J Controlled Release. 2003;93(3):377–387.
    1. Hammell D, Zhang L, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis. European j Pain. 2016;20(6):936–948.
    1. Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR. Human skin permeation of Δ8‐tetrahydrocannabinol, cannabidiol and cannabinol. J Pharmacy Pharmacology. 2004;56(3):291–297.
    1. Yim S, Lee J, Jo H, et al. Chrysanthemum morifolium extract and ascorbic acid-2-glucoside (AA2G) blend inhibits UVA-induced delayed cyclobutane pyrimidine dimer (CPD) production in melanocytes. Clin Cosmet Investig Dermatol. 2019;12:823–832.
    1. Bickers DR, Athar M. Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol. 2006;126(12):2565–2575.
    1. Dalmau N, Andrieu-Abadie N, Tauler R, Bedia C. Phenotypic and lipidomic characterization of primary human epidermal keratinocytes exposed to simulated solar UV radiation. J Dermatol Sci. 2018;92(1):97–105.
    1. Lee C. Collaborative power of nrf2 and pparγ activators against metabolic and drug-induced oxidative injury. Oxid Med Cell Longev. 2017;2017:1378175.
    1. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol. 2010;50:323–354.
    1. Juknat A, Pietr M, Kozela E, et al. Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Delta9-tetrahydrocannabinol in BV-2 microglial cells. Br J Pharmacol. 2012;165(8):2512–2528.
    1. Juknat A, Pietr M, Kozela E, et al. Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells. PLoS One. 2013;8(4):e61462.
    1. Casares L, García V, Garrido-Rodríguez M, et al. Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020;28:101321.
    1. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants. 2020;9(1):21.
    1. Gęgotek A, Atalay S, Domingues P, Skrzydlewska E. The differences in the proteome profile of cannabidiol-treated skin fibroblasts following uva or uvb irradiation in 2d and 3d cell cultures. Cells. 2019;8(9):995.
    1. Amaya F, Izumi Y, Matsuda M, Sasaki M. Tissue injury and related mediators of pain exacerbation. Curr Neuropharmacol. 2013;11(6):592–597.
    1. Stockbridge EL, Suzuki S, Pagán JA. Chronic pain and health care spending: an analysis of longitudinal data from the medical expenditure panel survey. Health Serv Res. 2015;50(3):847–870.
    1. Chan HN, Fam J, Ng B-Y. Use of antidepressants in the treatment of chronic pain. Annals Acad Med Singapore. 2009;38(11):974.
    1. Ryder S-A, Stannard CF. Treatment of chronic pain: antidepressant, antiepileptic and antiarrhythmic drugs. Continuing Education Anaesthesia, Critical Care Pain. 2005;5(1):18–21.
    1. Romero-Sandoval A, Bynum T, Eisenach JC. Analgesia induced by perineural clonidine is enhanced in persistent neuritis. Neuroreport. 2007;18(1):67–71.
    1. Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. PAIN®. 2012;153(9):1815–1823.
    1. Jones VM, Moore KA, Peterson DM. Capsaicin 8% topical patch (Qutenza)—a review of the evidence. J Pain Palliat Care Pharmacother. 2011;25(1):32–41.
    1. Peppin JF, Pappagallo M. Capsaicinoids in the treatment of neuropathic pain: a review. Ther Adv Neurol Disord. 2014;7(1):22–32.
    1. Donvito G, Nass SR, Wilkerson JL, et al. The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology. 2018;43(1):52–79.
    1. Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55, 212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol. 2001;133(4):586–594.
    1. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–2473.
    1. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4(8):1729–1743.
    1. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol. 2001;44(1 Suppl):S1–s12.
    1. Pulvirenti N, Nasca MR, Micali G. Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: a pilot study. Acta Dermatovenerologica Croatica. 2007;15(2).
    1. Petrosino S, Verde R, Vaia M, Allarà M, Iuvone T, Di Marzo V. Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis. J Pharmacology Experimental Therapeutics. 2018;365(3):652–663.
    1. Dimitriu PA, Iker B, Malik K, Leung H, Mohn WW, Hillebrand GG. New insights into the intrinsic and extrinsic factors that shape the human skin microbiome. mBio. 2019;10(4):e00839–00819.
    1. Nakagawa S, Hillebrand GG, Nunez G. Extracts containing carnosic acid and carnosol are potent quorum sensing inhibitors of staphylococcus aureus virulence. Antibiotics. 2020;9(4):149.
    1. Mediavilla V, Steinemann S. Essential oil of Cannabis sativa L. strains. J Int Hemp Assoc. 1997;4:80–82.
    1. Zengin G, Menghini L, Di Sotto A, et al. Chromatographic analyses, in vitro biological activities, and cytotoxicity of cannabis sativa l. Essential oil: A multidisciplinary study. Molecules. 2018;23(12):3266.
    1. Gupta K, Harvima IT. Mast cell‐neural interactions contribute to pain and itch. Immunol Rev. 2018;282(1):168–187.
    1. Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clinical Immunology. 2018;142(5):1375–1390.
    1. Meng J, Steinhoff M. Molecular mechanisms of pruritus. Current Res Translational Med. 2016;64(4):203–206.
    1. Ward SJ, Lefever TW, Rawls SM, Whiteside GT, Walker EA. Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats. Psychopharmacology. 2009;206(1):155–165.
    1. Bilir K, Anli G, Ozkan E, Gunduz O, Ulugol A. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212‐2, a cannabinoid receptor agonist. Clin Exp Dermatol. 2018;43(5):553–558.
    1. Pavon FJ, Bilbao A, Hernández-Folgado L, et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-3-hexyl-1H-1, 2, 4-triazole–LH 21. Neuropharmacology. 2006;51(2):358–366.
    1. Nattkemper LA, Tey HL, Valdes-Rodriguez R, et al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Investigative Dermatol. 2018;138(6):1311–1317.
    1. Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflammation Research. 2003;52(6):238–245.
    1. Haruna T, Soga M, Morioka Y, et al. S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission. Pharmacology. 2015;95(1–2):95–103.
    1. Maekawa T, Nojima H, Kuraishi Y, Aisaka K. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006;542(1–3):179–183.
    1. Caterina MJ, Pang Z. TRP channels in skin biology and pathophysiology. Pharmaceuticals. 2016;9(4):77.
    1. Tóth BI, Oláh A, Szöllősi AG, Bíró T. TRP channels in the skin. Br J Pharmacol. 2014;171(10):2568–2581.
    1. Tóth BI, Szallasi A, Bíró T. Transient Receptor Potential Channels and Itch: How Deep Should We Scratch? In: Pharmacology of Itch. Springer; 2015:89–133.
    1. Moore C, Gupta R, Jordt S-E, Chen Y, Liedtke WB. Regulation of pain and itch by trp channels. Neurosci Bull. 2018;34(1):120–142.
    1. Xie Z, Hu H. TRP Channels as Drug Targets to Relieve Itch. Pharmaceuticals. 2018;11:4.
    1. Yesilyurt O, Cayirli M, Sakin YS, Seyrek M, Akar A, Dogrul A. Systemic and spinal administration of FAAH, MAGL inhibitors and dual FAAH/MAGL inhibitors produce antipruritic effect in mice. Arch Dermatol Res. 2016;308(5):335–345.
    1. Tosun NC, Gunduz O, Ulugol A. Attenuation of serotonin-induced itch responses by inhibition of endocannabinoid degradative enzymes, fatty acid amide hydrolase and monoacylglycerol lipase. J Neural Transm. 2015;122(3):363–367.
    1. Schlosburg JE, Boger DL, Cravatt BF, Lichtman AH. Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus. J Pharmacology Experimental Therapeutics. 2009;329(1):314–323.
    1. Vaia M, Petrosino S, De Filippis D, et al. Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. Eur J Pharmacol. 2016;791:669–674.
    1. Stander S, Reinhardt HW, Luger TA. [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2006;57(9):801–807. German.
    1. Visse K, Blome C, Phan NQ, Augustin M, Ständer S. Efficacy of body lotion containing N-palmitoylethanolamine in subjects with chronic pruritus due to dry skin: a dermatocosmetic study. Acta Derm Venereol. 2017;97(5):639–641.
    1. Spradley JM, Davoodi A, Gee LB, Carstens MI, Carstens E. Differences in peripheral endocannabinoid modulation of scratching behavior in facial vs. spinally-innervated skin. Neuropharmacology. 2012;63(4):743–749.
    1. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150(5):613–623.
    1. Broughton GI, Janis JE, Attinger CE. The Basic Science of Wound Healing. Plast Reconstr Surg. 2006;117(7S):12S–34S.
    1. Ellis S, Lin EJ, Tartar D. Immunology of wound healing. Curr Dermatol Rep. 2018;7(4):350–358.
    1. Johnson TR, Gómez BI, McIntyre MK, et al. The cutaneous microbiome and wounds: new molecular targets to promote wound healing. Int J Mol Sci. 2018;19(9):2699.
    1. Zhao Z, Guan D, Liu W, et al. Expression of cannabinoid receptor I during mice skin incised wound healing course. Fa Yi Xue Za Zhi. 2010;26(4):241–245.
    1. Zheng J-L, Yu T-S, Li X-N, et al. Cannabinoid receptor type 2 is time-dependently expressed during skin wound healing in mice. Int J Legal Med. 2012;126(5):807–814.
    1. Wang LL, Zhao R, Li JY, et al. Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing. Eur J Pharmacol. 2016;786:128–136.
    1. Bort A, Alvarado-Vazquez PA, Moracho-Vilrriales C, et al. Effects of JWH015 in cytokine secretion in primary human keratinocytes and fibroblasts and its suitability for topical/transdermal delivery. Mol Pain. 2017;13:1744806916688220.
    1. Del Río C, Navarrete C, Collado JA, et al. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways. Sci Rep. 2016;6(1):21703.
    1. Ramot Y, Oláh A. Cover Image: neuroendocrine treatment of inherited keratin disorders by cannabinoids? British J Dermatol. 2018;178(6):1469.
    1. Chelliah MP, Zinn Z, Khuu P, Teng JMC. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatr Dermatol. 2018;35(4):e224–e227.
    1. Sangiovanni E, Fumagalli M, Pacchetti B, et al. Cannabis sativa L. Extract and Cannabidiol Inhibit in vitro Mediators of Skin Inflammation and Wound Injury. 2019;33(8):2083–2093.
    1. Dobrosi N, Tóth BI, Nagy G, et al. Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling. FASEB J. 2008;22(10):3685–3695.
    1. Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014;124(9):3713–3724.
    1. Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Research. 2018;7.
    1. Jin S, Lee MY. The ameliorative effect of hemp seed hexane extracts on the Propionibacterium acnes-induced inflammation and lipogenesis in sebocytes. PLoS One. 2018;13(8):e0202933. doi:10.1371/journal.pone.0202933
    1. Ali A, Akhtar N. The safety and efficacy of 3% Cannabis seeds extract cream for reduction of human cheek skin sebum and erythema content. Pak J Pharm Sci. 2015;28(4):1389–1395.
    1. Kim -S-S, Baik JS, Oh T-H, Yoon W-J, Lee NH, Hyun C-G. Biological activities of Korean citrus obovoides and citrus natsudaidai essential oils against acne-inducing bacteria. Biosci Biotechnol Biochem. 2008;72(10):2507–2513. doi:10.1271/bbb.70388
    1. Raman A, Weir U, Bloomfield S. Antimicrobial effects of tea‐tree oil and its major components on Staphylococcus aureus, Staph. epidermidis and Propionibacterium acnes. Lett Appl Microbiol. 1995;21(4):242–245. doi:10.1111/j.1472-765X.1995.tb01051.x
    1. Krause K, Foitzik K Biology of the hair follicle: the basics. Paper presented at: Seminars in cutaneous medicine and surgery 2006.
    1. Ramezani V, Honarvar M, Seyedabadi M, Karimollah A, Ranjbar AM, Hashemi M. Formulation and optimization of transfersome containing minoxidil and caffeine. J Drug Deliv Sci Technol. 2018;44:129–135. doi:10.1016/j.jddst.2017.12.003
    1. Skopp G, Strohbeck-Kuehner P, Mann K, Hermann D. Deposition of cannabinoids in hair after long-term use of cannabis. Forensic Sci Int. 2007;170(1):46–50. doi:10.1016/j.forsciint.2006.09.003
    1. Paul R, Williams R, Hodson V, Peake C. Detection of cannabinoids in hair after cosmetic application of hemp oil. Sci Rep. 2019;9(1):2582.
    1. Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nature Reviews Disease Primers. 2017;3(1):1–17. doi:10.1038/nrdp.2017.11
    1. Brodell LA, Mercurio MG. Hirsutism: diagnosis and management. Gend Med. 2010;7(2):79–87. doi:10.1016/j.genm.2010.04.002
    1. Wendelin DS, Pope DN, Mallory SB. Hypertrichosis. J Am Acad Dermatol. 2003;48(2):161–182. doi:10.1067/mjd.2003.100
    1. Telek A, Bíró T, Bodó E, et al. Inhibition of human hair follicle growth by endo- and exocannabinoids. FASEB J. 2007;21(13):3534–3541. doi:10.1096/fj.06-7689com
    1. Srivastava BK, Soni R, Patel JZ, et al. Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect. Bioorg Med Chem Lett. 2009;19(9):2546–2550. doi:10.1016/j.bmcl.2009.03.046
    1. Bodó E, Bíró T, Telek A, et al. A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol. 2005;166(4):985–998. doi:10.1016/S0002-9440(10)62320-6
    1. Borbíró I, Lisztes E, Tóth BI, et al. Activation of transient receptor potential vanilloid-3 inhibits human hair growth. J Investigative Dermatol. 2011;131(8):1605–1614. doi:10.1038/jid.2011.122
    1. Szabó IL, Herczeg-Lisztes E, Szegedi A, et al. Transient receptor potential vanilloid 4 is expressed in human hair follicles and inhibits hair growth in vitro. J Investig Dermatol. 2018.
    1. Chanasumon N, Sriphojanart T, Suchonwanit P. Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis. Drug Des Devel Ther. 2018;12:365. doi:10.2147/DDDT.S156467
    1. Khidhir KG, Woodward DF, Farjo NP, et al. The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias. FASEB J. 2013;27(2):557–567. doi:10.1096/fj.12-218156
    1. Zaher H, Gawdat HI, Hegazy RA, Hassan M. Bimatoprost versus mometasone furoate in the treatment of scalp alopecia areata: a pilot study. Dermatology. 2015;230(4):308–313. doi:10.1159/000371416
    1. Costin G-E, Hearing VJ. Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J. 2007;21(4):976–994.
    1. Baswan SM, Yim S, Leverett J, Scholten J, Pawelek J. Cytidine decreases melanin content in a reconstituted three-dimensional human epidermal model. Arch Dermatol Res. 2019;311(3):249–250. doi:10.1007/s00403-019-01897-x
    1. Hearing VJ. Milestones in melanocytes/melanogenesis. J Invest Dermatol. 2011;131(E1):E1. doi:10.1038/skinbio.2011.1
    1. Kawakami A, Fisher DE. The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Laboratory Investigation. 2017;97(6):649–656. doi:10.1038/labinvest.2017.9
    1. Zhou J, Ren T, Li Y, et al. Oleoylethanolamide inhibits α-melanocyte stimulating hormone-stimulated melanogenesis via ERK, Akt and CREB signaling pathways in B16 melanoma cells. Oncotarget. 2017;8(34):56868. doi:10.18632/oncotarget.18097
    1. Magina S, Esteves-Pinto C, Moura E, et al. Inhibition of basal and ultraviolet B-induced melanogenesis by cannabinoid CB 1 receptors: a keratinocyte-dependent effect. Arch Dermatol Res. 2011;303(3):201–210. doi:10.1007/s00403-011-1126-z
    1. Kim J, In S, Park Y, Park M, Kim E, Lee S. Deposition of JWH-018, JWH-073 and their metabolites in hair and effect of hair pigmentation. Anal Bioanal Chem. 2013;405(30):9769–9778. doi:10.1007/s00216-013-7423-y
    1. Hwang YS, Kim Y-J, Kim MO, et al. Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017;273:107–114. doi:10.1016/j.cbi.2017.06.005
    1. Turner CE, Elsohly MA, Boeren EG. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod. 1980;43(2):169–234. doi:10.1021/np50008a001
    1. Stahl V, Vasudevan K. Comparison of efficacy of cannabinoids versus commercial oral care products in reducing bacterial content from dental plaque: a preliminary observation. Cureus. 2020;12(1):e6809.
    1. Ali E, Almagboul A, Khogali S, Gergeir U. Antimicrobial Activity of Cannabis sativa L. Chinese Medicine 2012;3(1): 61–64. doi:10.4236/cm.2012.31010
    1. Rashid F, Butt FA, Nasreen S. In vitro antimicrobial and antioxidant activities of two medicinal plants against some clinically important bacteria. FUUAST J Biol. 2016;6(1):103–107.
    1. Lone TA, Lone RA. Extraction of cannabinoids from Cannabis sativa L. plant and its potential antimicrobial activity. Universal J Med Dentistry. 2012;1(4):51–55.
    1. Appendino G, Gibbons S, Giana A, et al. Antibacterial cannabinoids from Cannabis sativa: a structure− activity study. J Nat Prod. 2008;71(8):1427–1430. doi:10.1021/np8002673
    1. Wassmann CS, Højrup P, Klitgaard JK. Cannabidiol is an effective helper compound in combination with bacitracin to kill Gram-positive bacteria. Sci Rep. 2020;10(1):4112. doi:10.1038/s41598-020-60952-0
    1. Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF. NF-kappaB: an essential transcription factor in psoriasis. J Dermatol Sci. 2013;69(2):89–94. doi:10.1016/j.jdermsci.2012.11.002
    1. Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett. 2006;399(1–2):91–95. doi:10.1016/j.neulet.2006.01.047
    1. Khaksar S, Bigdeli MR. Intra-cerebral cannabidiol infusion-induced neuroprotection is partly associated with the TNF-alpha/TNFR1/NF-small ka, CyrillicB pathway in transient focal cerebral ischaemia. Brain Injury. 2017;31(13–14):1932–1943. doi:10.1080/02699052.2017.1358397
    1. Pucci M, Rapino C, Di Francesco A, Dainese E, D’Addario C, Maccarrone M. Epigenetic control of skin differentiation genes by phytocannabinoids. Br J Pharmacol. 2013;170(3):581–591. doi:10.1111/bph.12309
    1. Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci. 2007;45(2):87–92. doi:10.1016/j.jdermsci.2006.10.009
    1. Holland ML, Allen JD, Arnold JC. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008;591(1–3):128–131. doi:10.1016/j.ejphar.2008.06.079
    1. von Schaper E. Bial incident raises FAAH suspicions. Nat Biotechnol. 2016;34(3):223.
    1. Van Esbroeck AC, Janssen AP, Cognetta AB, et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science. 2017;356(6342):1084–1087. doi:10.1126/science.aaf7497
    1. Bai J, Zheng Y, Wang G, Liu P. Protective effect of D-limonene against oxidative stress-induced cell damage in human lens epithelial cells via the p38 pathway. Oxid Med Cell Longev. 2016;2016.
    1. Gulluni N, Re T, Loiacono I, et al. Cannabis essential oil: A preliminary study for the evaluation of the brain effects. Evidence-Based Complementary Alternative Medicine. 2018;2018.
    1. Klauke A-L, Racz I, Pradier B, et al. The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. European Neuropsychopharmacol. 2014;24(4):608–620. doi:10.1016/j.euroneuro.2013.10.008
    1. Bahi A, Al Mansouri S, Al Memari E, Al Ameri M, Nurulain SM, Ojha S. β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiol Behav. 2014;135:119–124. doi:10.1016/j.physbeh.2014.06.003
    1. Gertsch J, Leonti M, Raduner S, et al. Beta-caryophyllene is a dietary cannabinoid. Proc Nat Acad Sci. 2008;105(26):9099–9104. doi:10.1073/pnas.0803601105
    1. Katsuyama S, Mizoguchi H, Kuwahata H, et al. Involvement of peripheral cannabinoid and opioid receptors in β‐caryophyllene‐induced antinociception. European j Pain. 2013;17(5):664–675. doi:10.1002/j.1532-2149.2012.00242.x
    1. Raduner S, Majewska A, Chen J-Z, et al. Alkylamides from Echinacea are a new class of cannabinomimetics Cannabinoid type 2 receptor-dependent and-independent immunomodulatory effects. J Biological Chemistry. 2006;281(20):14192–14206. doi:10.1074/jbc.M601074200
    1. Chicca A, Raduner S, Pellati F, et al. Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. Int Immunopharmacol. 2009;9(7–8):850–858. doi:10.1016/j.intimp.2009.03.006
    1. Hohmann J, Rédei D, Forgo P, et al. Alkamides and a neolignan from Echinacea purpurea roots and the interaction of alkamides with G-protein-coupled cannabinoid receptors. Phytochemistry. 2011;72(14–15):1848–1853. doi:10.1016/j.phytochem.2011.06.008
    1. Hou -C-C, Chen C-H, Yang N-S, et al. Comparative metabolomics approach coupled with cell-and gene-based assays for species classification and anti-inflammatory bioactivity validation of Echinacea plants. J Nutr Biochem. 2010;21(11):1045–1059. doi:10.1016/j.jnutbio.2009.08.010
    1. Hudson JB. Applications of the Phytomedicine Echinacea purpurea (Purple Coneflower) in Infectious Diseases. BioMed Research International. 2012. doi:10.1155/2012/769896
    1. Hu C, Kitts DD. Studies on the antioxidant activity of Echinacea root extract. J Agric Food Chem. 2000;48(5):1466–1472.
    1. Hassanzadeh P. The CB 1 receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin. Neurochem Res. 2012;37(5):1112–1120. doi:10.1007/s11064-012-0716-2
    1. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin: miniperspective. J Med Chem. 2017;60(5):1620–1637. doi:10.1021/acs.jmedchem.6b00975
    1. Siemoneit U, Koeberle A, Rossi A, et al. Inhibition of microsomal prostaglandin E2 synthase‐1 as a molecular basis for the anti‐inflammatory actions of boswellic acids from frankincense. Br J Pharmacol. 2011;162(1):147–162. doi:10.1111/j.1476-5381.2010.01020.x
    1. Rempel V, Fuchs A, Hinz S, et al. Magnolia extract, magnolol, and metabolites: activation of cannabinoid CB2 receptors and blockade of the related GPR55. ACS Med Chem Lett. 2013;4(1):41–45. doi:10.1021/ml300235q
    1. Shen J-L, Man K-M, Huang P-H, et al. Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders. Molecules. 2010;15(9):6452–6465. doi:10.3390/molecules15096452
    1. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012;34(3):255. doi:10.4103/0253-7176.106022

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner